Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban

Bibliography

• Gaziano MJ. Global burden of cardiovascular disease. In: Braunwald E, editor. Heart Disease. 7th edition. Elsevier Saunders; Philadelphia 2005. p. 1-19
   Google Scholar
• Apostolakis S, Lip GY, Lane DA, Shantsila E. The quest for new anticoagulants: from clinical development to clinical practice. Cardiovasc Ther 2011;29:e12-22
   PubMed Web of Science ®Google Scholar
• Carson JL. Subcutaneous unfractionated heparin vs low-molecular-weight heparin for acute thromboembolic disease: issues of efficacy and cost. JAMA 2006;296:991-3
   PubMed Web of Science ®Google Scholar
• Aujesky D, Smith KJ, Cornuz J, Roberts MS. Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. Chest 2005;128:1601-10
   PubMed Web of Science ®Google Scholar
• Feinberg WM, Blackshear JL, Laupacis A, Prevalence, age distribution and gender of patients with atrial fibrillation. Arch Intern Med 1995;155:469-73
   PubMed Web of Science ®Google Scholar
• Krahn AD, Manfreda J, Tate RB, . The natural history of atrial fibrillation: incidence, risk factors and prognosis in the Manitoba follow-up study. Am J Med 1995;98:476-84
   PubMed Web of Science ®Google Scholar
• Torbicki A, Perrier A, Konstantinides S, . ESC Committee for Practice Guidelines (CPG). Guidelines on thediagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008;29:2276-315
   PubMed Web of Science ®Google Scholar
• Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 2006;26:41-8
   PubMed Web of Science ®Google Scholar
• Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22:1381-9
   PubMed Web of Science ®Google Scholar
• Tulinsky A. Molecular interactions of thrombin. Semin Thromb Hemost 1996;22:117-24
   PubMed Web of Science ®Google Scholar
• Liaw PCY, Becker DL, Stafford AR, . Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem 2001;276:20959-65
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40
   PubMed Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, . The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-99
   PubMed Web of Science ®Google Scholar
• Feistritzer C, Lenta R, Riewald M. Protease-activated receptors-1 and -2 can mediate endothelial barrier protection: role in factor Xa signaling. J Thromb Haemost 2005;3:2798-805
   PubMed Web of Science ®Google Scholar
• Khoo CW, Tay KH, Shantsila E, Lip GY. Novel oral anticoagulants. Int J Clin Pract 2009;63:630-41
   PubMed Web of Science ®Google Scholar
• Iwatsuki Y, Sato T, Moritani Y, Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. Eur J Pharmacol 2011;673:49-55
   PubMed Web of Science ®Google Scholar
• Iwatsuki Y, Shigenaga T, Moritani Y, . Biochemical and pharmacological profiles of YM150, an oral direct factor Xa inhibitor. Blood 2006;108:273A
   Web of Science ®Google Scholar
• Saitoh M, Kaku S, Funatsu T, Comparison of YM150, an oral, direct factor Xa inhibitor, with other antithrombotic agents in rodent venous and arterial thrombosis models. Blood 2007;110:374A
   Google Scholar
• Eriksson BI, Turpie AG, Lassen MR, ; ONYX study group. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007;5:1660-5
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Turpie AG, Lassen MR, ; ONYX-2 study group. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost 2010;8:714-21
   PubMed Web of Science ®Google Scholar
• Turpie AGG, Lip GYH, Minematsu K, . Safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation: a Phase II Study. Eur Heart J 2010;21(Suppl 1):173
   Google Scholar
• Lip GYH, Halperin JL, Petersen P, . Safety and tolerability of the oral factor Xa inhibitor, YM150 versus warfarin in 1297 patients with non-valvular atrial fibrillation: a dose confirmation study (OPAL-2). J Thromb Hemost 2011;9(Suppl 2):748
   Google Scholar
• Steg PG, Mehta SR, Jukema JW, . RUBY-1 Investigators. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011;32:2541-54
   PubMed Web of Science ®Google Scholar
• APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, . Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119:2877-85
   PubMed Web of Science ®Google Scholar
• Alexander JH, Lopes RD, James S, APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708
   PubMed Web of Science ®Google Scholar
• Oldgren J, Budaj A, Granger CB, . RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-9
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Mohanavelu S, . ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374:29-38
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD, . ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19
   PubMed Web of Science ®Google Scholar
• Murphy SA, Antman EM, Wiviott SD, ; TRITON-TIMI 38 Investigators. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008;29:2473-9
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2010;361:1045-57
   Web of Science ®Google Scholar
• Younis HS, Crosby J, Huh JI, . Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood 2012;119:2401-8
   PubMed Web of Science ®Google Scholar
• Cohen MG, Purdy DA, Rossi JS, . First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation 2010;122:614-22
   PubMed Web of Science ®Google Scholar